97168 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
DOSAGE REGIMENS FOR ANTI-CD19 AGENTS AND USES THEREOF
#2FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME
#3CD19 BINDING MOLECULES AND USES THEREOF
#4ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#5CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR THE TREATMENT OF CANCER
#6Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof
#7Novel Anti-Human Transferrin Receptor Antibody Capable of Penetrating Blood-Brain Barrier
#8METHODS OF ENGINEERING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
#9Primary T-Cell Expansion
#10ANTI-CD2 ANTIBODIES
#11ATP-dependent agonists of immune cells function as anticancer agents
#12METHODS OF CELL THERAPIES
#13Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#14MULTISPECIFIC PROTEINS AND RELATED METHODS
#15MUTATED FERRITIN PROTEIN
#16CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
#17DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS
#18GENOME-EDITED INVARIANT NATURAL KILLER T (INKT) CELLS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
#19CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
#20THE NOVEL MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1)
#21METHOD AND COMPOSITION FOR INDUCING TOLERANCE
#22FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF
#23CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
#24CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#25ANTI-CD2 ANTIBODIES
#26Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias
#27In vivo targeting of T cells for mRNA therapeutics
#28COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS
#29HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCER
#30ALLOREACTIVE IMMUNE CELL-DISTANCING DEVICE AND USES THEREOF FOR PROTECTING DONOR-DERIVED CELLS FROM ALLOREJECTION
#31REAGENTS FOR EXPANDING CELLS EXPRESSING RECOMBINANT RECEPTORS
#32BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES
#33MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF
#34NOVEL AGENTS AND USES THEREOF
#35Novel Monoclonal Antibodies to Programmed DEATH (PD-1)
#36TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF
#37TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
#38DELAYING PEAK EFFECT AND/OR EXTENDING DURATION OF RESPONSE
#39T-CELL DEPLETING THERAPIES
#40Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof
#41METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG
#42CELL SURFACE COUPLING OF NANOPARTICLES
#43Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#44Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
#45Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
#46Cell surface coupling of nanoparticles
#47USE OF AN ANTI-CD2 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
#48Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
#49CHIMERIC ANTIGEN RECEPTORS AND GENE EDITING OF CD2 FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES
#50Compositions and methods for using the CD2-based signaling pathways to block HIV infection
#51CD19 binding molecules and uses thereof
#52Primary T-cell expansion
#53COMPOSITION AND THERAPEUTIC ANTI-TUMOUR VACCINE
#54Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
#55EXTRACELLULAR VESICLES COMPRISING TARGETING AFFINITY DOMAIN-BASED MEMBRANE PROTEINS
#56Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
#57FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF
#58COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD2+ CELLS
#59TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF
#60Single domain antigen binding domains that bind human Trop2
#61Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
#62Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof
#63COMBINATION THERAPY
#64FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF
#65Anti-human CD73 antibody
#66CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR THE TREATMENT OF CANCER
#67GENOME-EDITED INVARIANT NATURAL KILLER T (INKT) CELLS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
#68THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
#69Monoclonal antibodies to programmed death 1 (PD-1)
#70CS1 SPECIFIC MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR
#71CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
#72Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
#73Targeting agent antibody conjugates and uses thereof
#74Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
#75Re-directed immunotherapy
#76Methods for reducing toxicity of a chemotherapeutic drug
#77Composition and therapeutic anti-tumour vaccine
#78Anti CD84 antibodies, compositions comprising same and uses thereof
#79Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
#80Anti-CS1 antibodies and antibody drug conjugates
#81Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
#82USE OF BLOCKING-REAGENTS FOR REDUCING UNSPECIFIC T CELL-ACTIVATION
#83Soluble universal ADCC-enhancing synthetic fusion gene and peptide technology and its use thereof
#84METHOD OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES
#85Anti CD84 antibodies, compositions comprising same and uses thereof
#86T-cell redirecting bispecific antibodies for treatment of disease
#87COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS
#88Cell surface coupling of nanoparticles
#89CS1 SPECIFIC MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR
#90T-cell redirecting bispecific antibodies for treatment of disease
#91Composition and therapeutic anti-tumour vaccine
#92IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF
#93METHOD OF TREATING A PATHOLOGICAL SYNDROME
#94Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
#95T-cell redirecting bispecific antibodies for treatment of disease
#96METHOD OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES
#97Anti-CS1 antibodies and antibody drug conjugates
#98Targeting agent antibody conjugates and uses thereof
#99BISPECIFIC ANTIBODIES AND USES THEREOF
#100Therapeutic use of anti-CS1 antibodies
#101NOVEL THERAPEUTIC TARGET AND DIAGNOSTIC MARKER FOR ASTHMA AND RELATED CONDITIONS
#102METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES
#103Therapeutic use of anti-CS1 antibodies
#104Method of treating hypertension disorder and a pharmaceutical agent
#105T-cell redirecting bispecific antibodies for treatment of disease
#106Therapeutic use of anti-CS1 antibodies
#107Therapeutic use of anti-CS1 antibodies
#108Therapeutic use of anti-CS1 antibodies
#109Therapeutic use of anti-CS1 antibodies
#110Therapeutic use of anti-CS1 antibodies
#111Compostition and therapeutic anti-tumour vaccine
#112METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS
#113METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS
#114CYTOTOXIC COMPOSITION
#115METHODS OF ADMINISTERING/DOSING CD2 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISORDERS OR INFLAMMATORY DISEASES
#116Method for administering homeopathically potentiated antibodies against mediator of inflammation
#117Method of treating disorders of the cardiovascular system and a pharmaceutical agent
#118Method of treating a pathological syndrome and a pharmaceutical agent
#119Method of treating a disorder or condition of viral etiology
#120Therapeutic use of anti-CS1 antibodies
#121Method for administering homeopathically potentized antibody
#122Methods for human allografting
#123Therapeutic use of anti-CS1 antibodies
#124Therapeutic use of anti-CS1 antibodies
#125THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
#126Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
#127METHODS FOR TREATING HIV INFECTED SUBJECTS
#128Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents
#129CHIMERIC PANCREAS
#130Methods for human allografting
#131Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
#132Method of treating a pathological syndrome and a pharmaceutical agent
#133Naturally occurring IgM antibodies that bind lymphocytes
#134USE OF ALLOGENEIC EFFECTOR CELLS AND ANTI-CS1 ANTIBODIES FOR SELECTIVE KILLING OF MULTIPLE MYELOMA CELLS
#135Method of treating a pathological syndrome and a pharmaceutical agent
#136Method of treating a pathological syndrome and a pharmaceutical agent
#137Method of treating a pathological syndrome and a pharmaceutical agent
#138Method of treating a pathological syndrome and a pharmaceutical agent
#139Method of treating a pathological syndrome and a pharmaceutical agent
#140Therapeutic target and diagnostic marker for asthma and related conditions
#141Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
#142Method of modulating memory effector T-cells and compositions
#143Compositions comprising a first agent which provides a primary activation signal to T cells and a second agent which stimulates an accessory molecule on the surface of T cells
#144Method of expressing gene in transgenic birds using retrovirus vector and transgenic birds thus obtained
#145Methods for selectively stimulating proliferation of T cells
#146Methods for selectively enriching TH1 and TH2 cells
#147Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
#148Methods and compositions for promoting immunopotentiation
#149Therapeutic use of anti-CS1 antibodies
#150Methods for treating HIV infected subjects
#151Compositions and methods for regulating lymphocyte activation
#152Activation and expansion of cells
#153Activation and expansion of cells
#154Therapeutic use of anti-CS1 antibodies